KIT and gastrointestinal stromal tumor: Although imatinib improves the prognosis of patients with advanced GIST [9], approximately 50% of patients develop tumor recurrence within 2 years, due to secondary mutations in c-kit at exons 13, 14, 16, 17 or 18 [5].